Taxorest
Longevity & Cellular HealthAlso known as: Lung Bioregulator, Khavinson Lung Peptide, Bronchial Bioregulator, Respiratory Bioregulator
Mechanism
Taxorest is a peptide bioregulator for the bronchial and lung tissue. The respiratory system faces constant assault from pollutants, pathogens, and oxidative stress. With age, lung capacity naturally declines and the bronchial lining becomes less resilient. Taxorest aims to restore proper gene expression in bronchial epithelial cells and alveolar tissue, supporting mucociliary clearance, surfactant production, and overall respiratory function. It is used by people with chronic respiratory conditions or those seeking to maintain lung health during aging.
Technical detail
Taxorest is a short-chain peptide bioregulator from the Khavinson series targeting bronchial epithelial cells, alveolar type I and type II pneumocytes, and bronchial smooth muscle. Proposed mechanism: nuclear DNA interaction to modulate expression of surfactant proteins (SP-A, SP-B, SP-C, SP-D) in type II pneumocytes — critical for alveolar surface tension regulation and innate immune defense. May normalize MUC5AC expression for optimal mucus viscosity and ciliary beat coordination (mucociliary clearance). Support for bronchial epithelial barrier integrity via tight junction protein expression (claudins, occludin). May modulate bronchial smooth muscle contractility gene expression. Consistent with Khavinson bioregulation paradigm. Published data limited to Khavinson group.
Effects
RESPIRATORY: Primary target system. Lung function (FEV1) declines ~25-30 mL/year after age 25 in non-smokers — accelerated by pollution, infection, and occupational exposure. Taxorest targets bronchial and alveolar cells: (1) Type II pneumocytes — produce pulmonary surfactant (SP-A, SP-B, SP-C, SP-D); surfactant reduces alveolar surface tension for efficient gas exchange and provides innate immune defense; surfactant production declines with age; (2) Bronchial epithelial cells — ciliated cells drive mucociliary clearance (mucus elevator); goblet cells produce mucus; Clara/Club cells produce protective secretory proteins; MUC5AC/MUC5B mucin gene balance affects mucus viscosity; (3) Alveolar macrophages — primary innate immune cells of the lung; phagocytose inhaled particles and pathogens. IMMUNE: Lungs are a major immune organ — constant interface with environmental pathogens. SP-A and SP-D are collectins that opsonize pathogens for macrophage clearance. Proper mucus composition and ciliary function are critical for trapping and clearing inhaled pathogens. CARDIOVASCULAR: Efficient gas exchange supports oxygen delivery. COPD and pulmonary fibrosis increase pulmonary vascular resistance, leading to right heart strain (cor pulmonale). Tier 3: Users report improved breathing capacity, easier exercise tolerance, reduced respiratory infections, and faster recovery from colds/flu.
Practitioner Guide
DOSING TIPS: Standard protocol: 1-2 capsules daily for 10-30 days, repeated every 3-6 months. Take with meals. For respiratory concerns: 2 capsules daily for 30 days. SUPPLEMENT SYNERGIES: NAC (N-acetyl cysteine, 600-1200mg/day) — mucolytic and glutathione precursor; thins mucus and provides antioxidant protection; strong evidence for COPD support. Quercetin (500-1000mg/day) — anti-inflammatory, mast cell stabilizer, supports bronchial epithelial integrity. Vitamin D (2000-5000 IU/day) — respiratory epithelial cells express VDR; deficiency associated with increased respiratory infections. Bronchogen (another Khavinson lung bioregulator — Ala-Glu-Asp) for complementary support. Omega-3s for anti-inflammatory support. CYCLING: Standard Khavinson protocol. CONTRAINDICATION NUANCES: Lung cancer — do not stimulate gene expression in neoplastic tissue. Active tuberculosis — treat infection first. Patients on inhaled corticosteroids — no known interactions but monitor. Pulmonary fibrosis (IPF) — use with caution; theoretical benefit but no data. STORAGE: Room temperature. PATIENT EDUCATION: Your lungs lose capacity every year after age 25 — it is the earliest-declining major organ system. This bioregulator supports the cells that keep your airways clear and your air sacs efficient. Combine with regular aerobic exercise, which is the strongest stimulus for maintaining lung function. If you are a current or former smoker, this is especially relevant. Get baseline spirometry (PFTs) to track lung function over time.
Research Summary
TIER 1 (Gold Standard): No Western clinical trials. TIER 2 (Strong): Khavinson bioregulation theory. Lung aging physiology well-characterized (ERS/ATS guidelines). Surfactant biology well-established. TIER 3 (Moderate): Khavinson group respiratory bioregulator publications. Related peptide Bronchogen (Ala-Glu-Asp) has more published data from Khavinson group. Practitioner reports. KEY FINDINGS: (1) Lung function decline begins early and is irreversible. (2) Supporting surfactant production and mucociliary clearance is a rational target. (3) No independent validation. GAPS: Standard Khavinson gaps.